Back to search

Peptide record

TPDB92164

FLAK 17 C Antibacterial Anticancer Antifungal Hemolysis Toxicity standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92164
FLAK 17 C
Antibacterial Anticancer Antifungal Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb iACP-DRLF Antifungipept CAFPdb dbAMP PD_Hemolysis
standard
No
A 15-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AntiCP 2.0, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
FAKALKALLKALKAL-NH2
Physicochemical Analysis
C78H139N19O16
RNDCEQGHIMPSTWYV
AL
1599.08
11.00
4
0
11
+4
-0.82
1.013
163.33
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
5
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
5
L
4
K
0
M
1
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 5 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 5 K: 4 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
15
C78H139N19O16
1599.08
11.00
+4
-0.82
1.013
Amidation
L
Linear
Free
Anticancer
FLAK peptides
Evidence Records 6 records
Evidence 1 Activity

Activity

LD50
LD50 =80 µg/ml
Anticancer
80 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

LD50 = µg/ml
Anticancer

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 3 Activity

Activity

LD50
LD50 =35 µg/ml
Anticancer
35 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 4 Activity

Activity

LD50
LD50 =30 µg/ml
Anticancer
30 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 5 Activity

Activity

LD50
LD50 =46 µg/ml
Anticancer
46 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 6 Activity

Activity

LD50
LD50 =30 µg/ml
Anticancer
30 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2